Articles tagged "Antibodies"

2020 American Transplant Congress
Comparison of Clinical Characteristics and Outcomes of Early Antibody-Mediated Rejection and Late Antibody-Mediated Rejection after Kidney Transplantation
G. Chen, Z. Wu, C. Wang, X. Liu, Q. Li, L. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
*Purpose: Antibody-mediated rejection(AMR) is a major risk factor for graft loss after kidney transplantation. Some AMR appeared within 6 months after kidney transplant, that we…
2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…
2020 American Transplant Congress
Outcomes of a Pre-Transplant Desensitization Protocol with Carfilzomib, Plasmapheresis, and IVIG for Broadly Sensitized Lung Transplant Candidates: A Case Series
S. Fredrick¹, C. Iasella², C. Moore¹, M. Mangiola³, Q. Xu³, C. Ensor⁴, D. Riciutti², C. LaFratte², P. Sanchez³, M. Morrell³, J. McDyer³, A. Zeevi³
¹Department of Pharmacy, UPMC Presbyterian, Pittsburgh, PA, ²University of Pittsburgh School of Pharmacy, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Department of Pharmacy, AdventHealth, Orlando, FL
*Purpose: The presence of anti-human leukocyte antigen (HLA) antibodies in lung transplant candidates leads to increased wait list times and antibody-mediated rejection (AMR) post-transplant. We…
2020 American Transplant Congress
Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome
R. Rattanavich, M. De Vera, T. Hoang, R. Villicana
Loma Linda University, Transplant Institute, San Bernadino, CA
*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT - donors have seroconverted but its impact on renal…
2020 American Transplant Congress
Clinical Significance of C4d and HLA-DSA on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients with Antibody-Mediated Rejection
W. Park, O. Kwon, Y. Kim, J. Paek, K. Jin, S. Park, S. Han
Internal Medicine, Keimyung University School of Medicine, Keimyung University Kidney Institute, Daegu, Korea, Republic of
*Purpose: The clinicopathological diagnosis of rejection after kidney transplantation (KT) was well defined by Banff classification. In the diagnosis of antibody-mediated rejection (AMR), the presence…
2020 American Transplant Congress
Identification of Eplet Mismatches Associated with De Novo Donor Specific HLA Antibody in a Pediatric Kidney Transplant Cohort
O. Charnaya, J. Jones, P. Chiang, M. C. Philogene, J. Garonzik-Wang
Johns Hopkins University, Baltimore, MD
*Purpose: While optimizing immunological matching will decrease the risk of de novo donor specific HLA antibody (dnDSA) formation and improve long-term graft function in pediatric…
2020 American Transplant Congress
Single Center Snapshot Experience of dd-cfDNA in Lung Transplantation
D. Levine, P. Ong, D. De Armond, E. Sako
University of Texas Health San Antonio, San Antonio, TX
*Purpose: Chronic lung allograft dysfunction (CLAD) is the primary etiology of graft failure and associated with poor survival post lung transplantation (LT). Risk factors for…
2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
J. M. Brennan¹, M. D. Stegall², C. A. Schinstock², R. L. Heilman³, L. M. Rebellato⁴, M. D. Samaniego-Picota⁵, D. Lesser⁴, M. J. Ghandi², J. L. Beaumont¹, M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…
2020 American Transplant Congress
Unusual Case of Delayed Onset Proteinuria in AT1R Antibody Mediated Rejection
K. Venkatachalam, L. Mackelaite, H. Dave
Nephrology and Hypertension, University of Louisville, Louisville, KY
*Purpose: Describing the nuances in treatment of Angiotensin receptor II Type I antibody mediated rejection*Methods: Complement-independent Angiotensin receptor II Type I antibodies (AT1R-Ab) have been…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)
S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…